Tag Archives: Michael Higgins

Analysts Offer Insights on Healthcare Companies: SCYNEXIS (NASDAQ: SCYX) and Outlook Therapeutics (NASDAQ: OTLK)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on SCYNEXIS (SCYX – Research Report) and Outlook Therapeutics (OTLK – Research Report) with bullish sentiments. SCYNEXIS (SCYX) Ladenburg Thalmann & Co. analyst

Zogenix (ZGNX) was Downgraded to a Hold Rating at Ladenburg Thalmann & Co.

Ladenburg Thalmann & Co. analyst Michael Higgins downgraded Zogenix (ZGNX – Research Report) to Hold today and set a price target of $35.00. The company’s shares closed last Monday at $52.62. According to TipRanks.com, Higgins is currently ranked with no

Ladenburg Thalmann & Co. Maintains Their Buy Rating on SCYNEXIS (SCYX)

In a report released today, Michael Higgins from Ladenburg Thalmann & Co. maintained a Buy rating on SCYNEXIS (SCYX – Research Report), with a price target of $6.00. The company’s shares closed last Monday at $1.05. According to TipRanks.com, Higgins

Ladenburg Thalmann & Co. Reaffirms Their Buy Rating on Cerecor (CERC)

In a report released today, Michael Higgins from Ladenburg Thalmann & Co. maintained a Buy rating on Cerecor (CERC – Research Report), with a price target of $10.00. The company’s shares closed last Monday at $3.37, close to its 52-week

Marinus (MRNS) Gets a Buy Rating from Ladenburg Thalmann & Co.

Ladenburg Thalmann & Co. analyst Michael Higgins maintained a Buy rating on Marinus (MRNS – Research Report) today and set a price target of $5.00. The company’s shares closed last Monday at $1.09, close to its 52-week low of $0.77.

Eiger Biopharmaceuticals (EIGR) Receives a Buy from Ladenburg Thalmann & Co.

In a report released today, Michael Higgins from Ladenburg Thalmann & Co. maintained a Buy rating on Eiger Biopharmaceuticals (EIGR – Research Report), with a price target of $28.00. The company’s shares closed last Monday at $10.97. According to TipRanks.com,